Literature DB >> 18160810

Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure.

R Inauen, R Cathomas, T Boehm, D Koeberle, B C Pestalozzi, S Gillessen, R von Moos.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160810     DOI: 10.1159/000112828

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


× No keyword cloud information.
  7 in total

Review 1.  Practical guidelines for dose individualization of anticancer targeted drugs.

Authors:  María Isabel Sáez; Cristina Quero; José Manuel Trigo; Begoña Muros; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-10-12       Impact factor: 3.405

2.  A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.

Authors:  Ryan M Bolonesi; Jane E Rogers; Imad Shureiqi
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 3.  Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).

Authors:  Laura Cosmai; Maurizio Gallieni; Wanda Liguigli; Camillo Porta
Journal:  J Nephrol       Date:  2016-05-06       Impact factor: 3.902

4.  Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.

Authors:  Sachin Gupta; Venkata Parsa; Lance K Heilbrun; Daryn W Smith; Brenda Dickow; Elisabeth Heath; Ulka Vaishampayan
Journal:  Anticancer Drugs       Date:  2011-09       Impact factor: 2.248

Review 5.  Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis.

Authors:  Tzewah V Leung; Mitchell E Hughes; Christine G Cambareri; Daniel J Rubin; Beth Eaby-Sandy
Journal:  J Adv Pract Oncol       Date:  2018-09-01

Review 6.  [Cancer patients in operative intensive care medicine].

Authors:  T Annecke; A Hohn; B Böll; M Kochanek
Journal:  Anaesthesist       Date:  2018-02       Impact factor: 1.041

Review 7.  [Cancer patients in operative intensive care medicine].

Authors:  Thorsten Annecke; Andreas Hohn; Boris Böll; Matthias Kochanek
Journal:  Wien Klin Mag       Date:  2018-02-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.